Podium to Practice: Chicago 2025 – Melanoma: C-IT NEO

OR
Please enter your username or email address. You will receive an email message to log in.
Explore more from your favourite experts – click their name to access their entire library of content.

Chair

Speakers
Studies / Trials Discussed
9513 – Single dose of neoadjuvant ipilimumab and nivolumab in resectable melanoma with CD8+ cell imaging: Interim results of the C-IT Neo trial.
Studies/trials discussed:
9513 – Single dose of neoadjuvant ipilimumab and nivolumab in resectable melanoma with CD8+ cell imaging: Interim results of the C-IT Neo trial.
©2025 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement.
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.